podcast

Market Access

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.

Patients

FH25 limited series podcast - Denise Silber

FH25: Exploring the intersection of patients, HCPs, and tech...

In a new FH25 podcast, Denise Silber, founder of Basil Strategies and Doctors 2.0, discusses the intersection of HCPs, patients, and technology.

Oncology

pharmaphorum podcast Episode 205a - Amy Burroughs, Terns Pharmaceuticals

Doing good in people’s lives: Amy Burroughs discusses CML

Amy Burroughs, CEO, Terns Pharmaceuticals, discusses available treatments for CML, the potential of allosteric TKIs, and the wider oncology landscape.

Sales & Marketing

Frontiers Health limited series episode 3: Steve Seuntjens

FH25: Individual centric investing with Steve Seuntjens

In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.

Sales & Marketing

pharmaphorum podcast Episode 204a - Brian Coane, Leith

Pharma and health advertising: Brian Coane on the necessity ...

Brian Coane, health partner at Leith, talks sensitivity, maximum impact, and overcoming the fear of getting humour in pharma advertising wrong.

R&D

pharmaphorum podcast Episode 203a: Ali Pashazadeh, Treehill

The glimmer of opportunity behind the storm: Ali Pashazadeh ...

Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.